Physician profile
Michelle Son
NPI 1760175897
$3,719.18
in general payments reported to CMS, 2019-2025
49 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $463 · 2024: $2,002 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,519 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,519.28 |
| Education | $199.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $436.90 | 2023-2025 | Jakafi, Jakafi, Monjuvi |
| Janssen Biotech, INC. | $289.49 | 2023-2025 | Darzalex, Carvykti, Tecvayli |
| Pfizer INC. | $216.82 | 2024-2025 | |
| Gilead Sciences, INC. | $213.53 | 2024 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $172.04 | 2023-2025 | Lynparza, Imfinzi, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $164.14 | 2023-2025 | Opdivo |
| Eisai INC. | $163.78 | 2023-2024 | |
| Abbvie INC. | $159.46 | 2023-2025 | |
| My01 INC. | $144.79 | 2024 | My01 Continuous Compartmental Pressure Monitor |
| Regeneron Healthcare Solutions, INC. | $129.69 | 2023-2025 | Libtayo |
| Sobi, INC | $129.53 | 2024 | |
| Lilly USA, LLC | $122.43 | 2023-2025 | Verzenio, Jaypirca |
| Novartis Pharmaceuticals Corporation | $103.54 | 2024-2025 | |
| Springworks Therapeutics, INC. | $89.28 | 2024 | Ogsiveo |
| Beigene USA, INC. | $88.11 | 2024 | Brukinsa |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $76.87 | 2024-2025 | Vyloy, Cresemba, Padcev |
| Genmab U.S., INC. | $52.72 | 2023-2024 | Epkinly |
| Amgen INC. | $49.64 | 2024 | Prolia, Evenity, Krystexxa |
| Emd Serono, INC. | $49.16 | 2025 | |
| Beone Medicines USA, INC. | $47.27 | 2025 | Brukinsa |
| Servier Pharmaceuticals LLC | $47.02 | 2024-2025 | |
| Genentech USA, INC. | $44.73 | 2023-2024 | Tecentriq Hybreza, Tecentriq, Lunsumio |
| Celgene Corporation | $43.47 | 2024-2025 | Reblozyl |
| Coherus Oncology, INC. | $41.75 | 2024 | |
| Agios Pharmaceuticals, INC. | $40.59 | 2024-2025 | Pyrukynd |
| Fennec Pharmaceuticals, INC. | $38.58 | 2024-2025 | Pedmark, Fyarro |
| Geron Corporation | $35.55 | 2025 | Rytelo |
| Deciphera Pharmaceuticals INC. | $34.75 | 2025 | Romvimza, Qinlock |
| Daiichi Sankyo INC. | $32.45 | 2023-2025 | Datroway, Enhertu |
| Glaxosmithkline, LLC. | $32.44 | 2024 | Ojjaara |
| Avyxa Pharma, LLC | $29.15 | 2025 | |
| Array Biopharma INC | $28.62 | 2025 | Mektovi, Lorbrena, Braftovi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.01 | 2025 | |
| Stemline Therapeutics INC. | $25.94 | 2023 | Orserdu |
| Caris Mpi, INC. | $25.92 | 2025 | Mi Cancer Seek |
| Pharmaessentia USA Corporation | $24.20 | 2024 | Besremi |
| Immunogen, INC. | $23.95 | 2023 | Elahere |
| Rigel Pharmaceuticals, INC. | $23.64 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Sumitomo Pharma America, INC. | $23.00 | 2023 | Orgovyx |
| Syndax Pharmaceuticals, INC. | $22.82 | 2025 | |
| Invivyd INC | $22.77 | 2024 | Pemgarda |
| Karyopharm Therapeutics INC. | $22.43 | 2025 | Xpovio |
| Seagen INC. | $21.48 | 2023 | Padcev |
| Aadi Bioscience, INC. | $21.23 | 2024 | Fyarro |
| Spectrum Pharmaceuticals INC. | $19.99 | 2025 | Rolvedon |
| Legend Biotech USA INC. | $18.97 | 2025 | Carvykti |
| Exelixis INC. | $17.82 | 2024 | Cabometyx |
| Pharmacosmos Therapeutics INC. | $16.78 | 2024 | Monoferric |
| Recordati_rare_diseases_inc. | $13.94 | 2024 | Panhematin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Son listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.